From the Spring 2010 edition of the magazine: From the hypoallergenic cat to herbal tabs for asthma, to testing for allergy from birth, Allergic Living investigates what’s in the research pipeline.
Idea: Hypoallergenic Cat
What’s Involved: Genetically engineering a cat that doesn’t have the gene that makes Fel d 1 protein, which causes the majority of allergic reaction. Once a colony of hypoallergenic cats is established, kittens could be bred using “traditional” methods.
Where We Stand: In 2006 a company called Allerca Inc. claimed to have bred the world’s first hypoallergenic kittens and Time magazine hailed them as one of the best inventions of the year.
But the company and its founder have been the subject of controversy, with the media and a dedicated website questioning whether the firm, now called Lifestyle Pets, really has sneeze-free cats.
But this is not the only company in the hunt for the hypoallergenic kitty. Dr. David Avner, an emergency room physician in Denver, has been working with molecular biologists on silencing the Fel d 1 gene for years, and so far has come up empty-handed.
In the summer of 2009, his team thought they had successfully knocked out the gene, which could lead to the breakthrough they’ve hoped for.
While Avner admits to being “optimistic” in predicting when his company, Felix Pets, will have cats on the market, he says there’s little doubt that in 10 years, a hypoallergenic cat will be in people’s homes.
“Without question, someone is going to do it. It’s too obvious an application of the technology, and the desire for people to have allergen-free cats is too high for it to go unrealized.”
Idea: Herbal Tablets for Asthma
What’s Involved: The Antiasthma Herbal Formula (ASHMI) is a tablet containing three traditional Chinese herbs. A study of patients in China shows it improves lung function and reduces use of bronchodilators.
Where We Stand: Dr. Xiu-Min Li at the Mount Sinai School of Medicine and her colleagues continue to study ASHMI in mice and people, comparing it to using corticosteroids. New, unpublished data show that eight weeks after mice stop taking the corticosteroids, their asthma symptoms return when they are exposed to triggers.
However, the mice on the herbal formula are still protected eight weeks later. Safety studies in humans have been completed, and Phase 2 efficacy studies are continuing.
One of the benefits to using ASHMI, instead of a steroid, is that there are fewer side effects, such as weight gain. However, Li says corticosteroids will be the standard treatment for asthma for years to come.
“The practical protocol will be to have a herbal remedy that will reduce the steroid’s side effects and help to maintain the protective effect,” she says.
Idea: Quick-Acting Allergy Shots
What’s Involved: Currently, immunotherapy to environmental allergies such as trees, grass, ragweed and cats, sometimes called allergy shots, requires numerous needles over several years. The shots also carry the risk of anaphylaxis in some individuals. Now, a few companies are developing therapies to make the treatment process far shorter and also safer.
Where We Stand: Swiss firm Cytos Biotechnology has developed a vaccine for environmental allergies that doesn’t use the allergen, but instead takes a virus-like particle that’s easily recognized by the immune system and stuffs it with a DNA sequence to stimulate the immune response.
The idea is to minimize side effects and the potential for anaphylaxis associated with current allergy shots.
To date, Cytos has found its shots to be effective for people with allergy symptoms from dust mite and cat allergies. Results are expected this spring from a study of patients with allergic asthma. The company hopes to partner with a leading pharmaceutical manufacturer once the studies are completed.
A U.K. company called Allergy Therapeutics has developed a modified form of immunotherapy to grass, ragweed, and tree pollen that it believes is effective after just four shots over three weeks. The company’s process involves chemically modifying natural allergens to make the vaccine safer to administer at higher doses.
The modified allergens are also supposed to be active for longer in the body, and are given along with an adjuvant that boosts the immune system’s response and encourages allergen tolerance. The company hopes to launch the “grass” versions of the vaccine in some European countries within the next two years.
Another U.K. company, Circassia, is in late-stage development of vaccines for ragweed, dust mites and cat allergy. These vaccines use small bits of the allergen, rather than a whole protein, lessening the risk of reaction to the shot.
Next: Predicting, Preventing Allergy